Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 12, 2009, Pages 1191-1195

  Gadioli, A L N ^a   Nogueira, B V ^a   Arruda, R M P ^a   Pereira, R B ^a   Meyrelles, S S ^a   Arruda, J A ^a   Vasquez, E C ^a,b  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Depto de Ciencias Fisiologicas   (Brazil)

Author keywords

Apolipoprotein E; Atherosclerosis; Mice; Rapamycin; Sirolimus; Vascular responsiveness

Indexed keywords

ACETYLCHOLINE; APOLIPOPROTEIN E; CHOLESTEROL; NITROPRUSSIDE SODIUM; NORADRENALIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA WALL; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; MALE; MESENTERIC ARTERY; MOUSE; NONHUMAN;

ANIMALIA; MUS; RODENTIA;

EID: 73349106214     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009005000036     Document Type: Article

References (27)

1. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35: 7S-14S.
2. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996; 58: 373-395.
3. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-492.
4. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-2283.
5. Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 2002; 87: 305-307.
6. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
7. Fuke S, Maekawa K, Kawamoto K, Saito H, Sato T, Hioka T, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J 2007; 71: 220-225.
8. Hamilos MI, Ostojic M, Beleslin B, Sagic D, Mangovski L, Stojkovic S, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008; 51: 2123-2129.
9. Brito FS Jr, Rosa WC, Arruda JA, Tedesco H, Pestana JO, Lima VC. Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia. Catheter Cardiovasc Interv 2005; 64: 413-418.
10. Milliard S, Silva A, Blaise G, Chen H, Xu D, Qi S, et al. Rapamycin's effect on vasomotion in the rat. Transplant Proc 1998; 30: 1036-1038.
11. Neto MM, Di Marco GS, Casarini DE, Lima VC, Campos AH. Orally administered rapamycin does not modify rat aortic vascular tone. J Cardiovasc Pharmacol 2007; 49: 96-99.
12. Waksman R, Pakala R, Burnett MS, Gulick CP, Leborgne L, Fournadjiev J, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 2003; 4: 34-38.
13. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46: 481-486.
14. Ruygrok PN, Muller DW, Serruys PW. Rapamycin in cardiovascular medicine. Intern Med J 2003; 33: 103-109.
15. Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 2008; 118: 1817-1827.
16. Arruda JA, Costa MA, Brito FS Jr, Tedesco H, Barbosa AH, Ribeiro EP, et al. Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients. Am J Cardiol 2003; 91: 1363-1365.
17. Rodriguez AE, Rodriguez AM, Vigo CF, Fernandez PC, Llaurado C, Vetcher D, et al. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart 2005; 91: 1433-1437.
18. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 1992; 89: 4471-4475.
19. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343-353.
20. Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension 2005; 46: 932-936.
21. Nogueira BV, Peotta VA, Meyrelles SS, Vasquez EC. Evaluation of aortic remodeling in apolipoprotein E-deficient mice and renovascular hypertensive mice. Arch Med Res 2007; 38: 816-821.
22. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562-569.
23. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway. Atherosclerosis 2004; 172: 31-38.
24. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC. Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 2005; 37: 1880-1884.
25. Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997; 17: 1148-1156.
26. Basso MD, Nambi P, Adelman SJ. Effect of sirolimus on the cholesterol content of aortic arch in ApoE knockout mice. Transplant Proc 2003; 35: 3136-3138.
27. Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Antiatherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292: H2721-H2728.